乐观
$33.09
情景价格
$16.630
+0.151 (+0.91%)收盘时
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.
Perrigo Company PLC is a good buy right now, trading at $16.63 with a forward P/E ratio of 5.97, suggesting it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong 20-day change of +22.64%, indicating positive momentum. However, investors should be cautious due to a recent net income loss of $398.6 million in Q1 2026, which poses a risk to future profitability.
JPMorgan
$15
2026-02-27
JPMorgan
2026-02-27
目标价
$15
Canaccord
$17
2026-02-27
Canaccord
2026-02-27
目标价
$17
JPMorgan
$18
2025-12-15
JPMorgan
2025-12-15
目标价
$18
Canaccord
$20
2025-11-06
Canaccord
2025-11-06
目标价
$20
JPMorgan
$20
2025-11-06
JPMorgan
2025-11-06
目标价
$20
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Perrigo Shares Surpass Analyst Target Price of $15.25

Perrigo to Participate in Barclays Global Consumer Conference

Perrigo Shares Surpass Analyst Target Price of $14.50

Perrigo Faces Financial Challenges Amid CEO Transition

Perrigo CEO Abruptly Departs Amid Weak Financial Performance
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Perrigo Company PLC is a good buy right now, trading at $16.63 with a forward P/E ratio of 5.97, suggesting it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong 20-day change of +22.64%, indicating positive momentum. However, investors should be cautious due to a recent net income loss of $398.6 million in Q1 2026, which poses a risk to future profitability.
18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。